Equibles does not estimate personal net worth.
Get an email with a short summary when Madrigal Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get MDGL alertsMardi Dier is recorded as CFO at Madrigal Pharmaceuticals, Inc. (MDGL). The newest filing on record that lists Mardi Dier as CFO at Madrigal Pharmaceuticals, Inc. (MDGL) is dated April 28, 2026. Earlier roles on record: CFO at Ultragenyx Pharmaceutical Inc. (RARE) until November 15, 2022. Ultragenyx Pharmaceutical Inc. reported in an 8-K filed November 10, 2022 that Mardi Dier resigned as Executive Vice President and Chief Financial Officer, effective November 15, 2022. The proxy statement of Madrigal Pharmaceuticals, Inc. reports total compensation of $6,085,089 for Mardi Dier in fiscal 2025, including a base salary of $566,042. Disclosed compensation is on record for 5 fiscal years. Mardi Dier has spoken on 17 earnings calls and 2 other investor events across 2 companies, most recently for Madrigal Pharmaceuticals, Inc. on July 30, 2026. Those appearances were for Madrigal Pharmaceuticals, Inc. (MDGL) and Ultragenyx Pharmaceutical Inc. (RARE). Madrigal Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Mardi Dier spoke on are classified in the Healthcare sector. Other leadership on record at Madrigal Pharmaceuticals, Inc. includes Bill Sibold (CEO and Board Member), Julian C. Baker (Chairman and Board Member), Brian J. Lynch (General Counsel) and 7 others.
“On November 10, 2022, Ultragenyx Pharmaceutical Inc. (the “Company”) announced that Mardi Dier had informed the Company of her decision to voluntarily resign from her position as the Company’s Executive Vice President and Chief Financial Officer, effective as of November 15, 2022, to pursue another opportunity.”
“Turning to slide 20 and a summary of our financial results. We delivered another strong quarter, with second quarter 2026 net sales of $364.3 million, representing 71% growth year over year.”
“As Bill said, you know, we are in excellent shape with respect to market access and growth to net in total. We take very seriously at the company and the team's done an excellent job managing growth to net to date.”
“Turning to slide 15 in a summary of our financials. First quarter, 2026 net sales totaled $311.3 million, up 127% year over year. We're off to a strong start in 2026.”
“So no more narrowing. we thought we did a really good job in looking at the analogs. A company's, you know, big brand in looking at the effect, the Q1 effect, that they're down mid to high single digits, you know, every Q1.”
“Turning to slide 20 and a summary of our financials. Fourth quarter 2025 net sales totaled $321.1 million, reflecting another quarter of strong demand and bringing full year 2025 net sales to $958.4 million.”
Start not stated–present
Last confirmed April 28, 2026
Start not stated–2022-11-15
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Madrigal Pharmaceuticals, Inc. (MDGL) | Executive Vice President and Chief Financial Officer | $566,042 | $6,085,089 |
| 2024 | Madrigal Pharmaceuticals, Inc. (MDGL) | Executive Vice President and Chief Financial Officer | $464,679 | $8,751,912 |
| 2022 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $607,346 | $4,436,756 |
| 2021 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $561,539 | $3,331,874 |
| 2020 | Ultragenyx Pharmaceutical Inc. (RARE) | Former Chief Financial Officer and Executive Vice President | $116,346 | $6,120,642 |
